Status:
COMPLETED
Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma
Lead Sponsor:
West China Hospital
Conditions:
Glioma
Glioma : Oligodendroglioma or Astrocytoma
Eligibility:
All Genders
18-65 years
Brief Summary
Although surgical resection improves overall survival in patients with diffuse Low-grade gliomas (DLGG), it can also result in deterioration of neurocognitive function, which are poorly understood and...
Eligibility Criteria
Inclusion
- Histopathologically proven DLGG based on 2021 WHO criteria
- Age ≥ 18 years,
- Karnofsky Performance Status ≥ 70%,
- Tumor involved unilateral left frontal lobe and did not reach the central sulcus.
Exclusion
- With previous treatment before image acquisition,
- Presenting cognitive impairment pre-operatively based on The Montreal Cognitive Assessment (MoCA)
- Survival of less than 3 months post-surgery
- Lack of compliance with neurocognitive assessments in 3-month and 1-year after surgery
Key Trial Info
Start Date :
May 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT06885333
Start Date
May 1 2016
End Date
December 1 2024
Last Update
March 20 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.